The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Evidence

effect size

Magnitude, not just direction or significance.

214 topics 77 solved Group: Evidence

Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis

214 topics · page 6 of 8

TopicParticipantsRepliesViewsActivity
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…
EKEPAKTWJD+71 80 38k 11mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 2 ( Lancet ,…
KHSCGIMYG+150 163 22k 11mo
Coming back to: An 18-month record including the parts that went badly
Posting this under the heading it deserves: An 18-month record including the parts that went badly Everything below is what sits behind that. Longitudinal report with the method stated, because a number…
SVAKRZACN+83 89 52k 12mo
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…
SGSRSTSLFR+41 45 24k 12mo
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
LSCLPM 2 1.9k 12mo
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
IDNMTNAFMB+27 31 671 12mo
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of…
ELPBLCMNBP+39 43 7.3k 12mo
Regression to the mean in progress reports
On the subject in the title: Regression to the mean in progress reports Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the discussion…
HAAMTFAVDM+30 34 49k 12mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…
SVDSNBOOMP+12 16 50k 12mo
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a…
ADACLMAK+74 79 2.3k 13mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…
NEKCMALC+48 53 31k 13mo
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
NPFSMLAJS+16 20 22k 13mo
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…
VMLADNWMD+58 64 17k 13mo
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
DJTVGHIO+61 65 2k 13mo
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…
SRBIHIPINO+128 142 38k 13mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…
CBTNNAFEKK+65 71 4.6k 13mo
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
EAKBTEMAK+30 34 64k 14mo
Pre-registering a personal experiment, seriously
Pre-registering a personal experiment, seriously — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SUSTAIN 6 ( N Engl J Med , 2016) and finding the…
PADAVSSJL+96 119 58k 14mo
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with LEADER ( N Engl J Med ,…
RCMICBMRPN+117 128 7.2k 14mo
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
CLBKSS 2 41k 14mo
Second pass at: Designing a personal experiment that could change your mind
Second pass at: Designing a personal experiment that could change your mind Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please…
JSJISTGBM+39 44 632 14mo
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
VRRIJV 2 6.9k 14mo
Coming back to: A critique that turned out to be unfair, retracted by its author
A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not…
IAQLJB 2 1.3k 14mo
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…
KBZOKOJMTV+55 61 60k 15mo
Journal club: STEP 4 and what a withdrawal design can prove — one year on
Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024).…
TDSVOFSOCT+56 62 34k 15mo
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…
RMCCYMRMJW+149 159 30k 15mo
Follow-up: Journal club: the retatrutide phase 2 obesity paper
On the subject in the title: Journal club: the retatrutide phase 2 obesity paper Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not…
NDNRRRSIS+20 24 8.7k 16mo
About the Progress reports category
Longitudinal self-reports with the method stated. Scales, tape measures, and their error bars. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
JMSLTSANHN 4 139 16mo
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
MENVRFCHKB+93 108 35k 16mo